Observational Study of Iris Tumors
Oregon Health and Science University · with National Eye Institute (NEI) · NCT03809585
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 100
- US sites recruiting
- 1
- Study start
- June 20, 2018
- Record last updated
- September 9, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is an observational study using OCT angiography to assist with tumor characterization in melanotic and amelanotic iris lesions. OCT angiography data from healthy eyes will be compared to eyes with various types of iris tumors.
Conditions: Iris Tumor
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria for tumor group
- Eyes with diagnosis of melanotic or amelanotic iris tumors
Inclusion Criteria for healthy control group:
- Eyes without iris defects or lesions
Exclusion Criteria (both groups):
- Inability to give informed consent
- Inability to maintain stable fixation for OCT imaging
- Inability to commit to required study visits
- Eyes with concurrent retinal diseases, glaucoma, or conditions that in the opinion of the investigators might affect iris circulation
- Mature cataracts if found to limit visual potential to worse than 20/40
Recruiting US locations
Oregon Health & Science University
Portland, OR 97239
Site contact: Denzil Romfh, OD · 503-494-4351 · romfhd@ohsu.edu
Study contacts (from the official record)
- Denzil Romfh, OD · 503-494-4351 · romfhd@ohsu.edu
- Humberto Martinez, COT · 503-494-7712 · martinhu@ohsu.edu
Similar studies in Oregon
All healthy volunteers studies in Oregon →- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Bend, OR + 18 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingHealthy volunteersPhase 1/Phase 2
Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination
Oregon Health and Science University
- Location
- Portland, OR
- Eligibility basics
- Ages 20–49
- RecruitingHealthy volunteersEarly Phase 1
Monoferric for Prenatal Iron Deficiency
Oregon Health and Science University
- Location
- Portland, OR
- Eligibility basics
- Ages 18–65 · Women only
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Portland, OR + 55 other US sites
- Eligibility basics
- Ages 18–79